Caris Life Sciences delivered record Q3 2026 revenue of $275.4M, up 27%, while raising full-year guidance and expanding its oncology platform into monitoring and MRD markets.
Caris Life Sciences reported total revenue of $755.2 million for the nine months ended September 30, 2026, a significant increase from $519.1 million in the prior year period. The company achieved a net income from operations of $51.5 million for the first nine months of 2026, compared to an operating loss of $43.3 million in 2025, driven primarily by growth in molecular profiling services.
Caris Life Sciences reported Q3 2026 revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling clinical case volume. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reported positive net income of $15.3 million for the quarter.
Term
Q3 2026
“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year. Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”
Caris Life Sciences announced that its management team will use a formal investor presentation for meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference beginning September 14, 2026. The presentation will be made available on the company's investor relations website.
Counterparty
Morgan Stanley 24th Annual Global Healthcare Conference